Researchers are on the brink of reveling strong links between the human gut biome and the health of the individual. The potential of this research seems limitless. The human gut biome is responsible for all sorts of conditions, ranging from inflammatory bowel disease to diabetes, multiple sclerosis, autism, cancer, and AIDS. Furthering our understanding of this biome could lead to cures for these conditions.
Soon, the first microbiome therapies will be available on the market for purchase. Rebiotix, the first acquisition of a microbiome company, is currently working on developing a therapy for C. difficile infections. In an interview, Lee Jones, founder and CEO of Rebiotix, said
“It has become evident through research that the microbiota that humans carry have a significant impact on human health, [The C. difficile therapy] has the potential to be the first human gut microbiome product approved anywhere in the world.”
The C. difficile therapy would mark the first human gut biome therapy on the market, a major advance in medicine. This year is supposed to be an inflection point for human gut biome research. It is expected that research will finally show results proving that the therapies have effects on humans. If this comes true, the future for microbiome medicine is bright.